v3.25.1

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue:
Total revenue	$ 6,457	$ 8,769
Cost of revenue:
Total cost of revenue	3,519	5,945
Operating expenses:
Research and development	2,370	9,779
Selling, general and administrative	9,033	19,088
Intangible assets and other long-lived assets impairment	0	448
Restructuring costs	0	4,632
Total operating expenses	11,403	33,947
Loss from operations	(8,465)	(31,123)
Other income (expense):
Interest income	290	1,044
Other income (expense)	5,080	(1,361)
Total other income (expense)	5,370	(317)
Loss before income taxes	(3,095)	(31,440)
Benefit (provision) for income taxes	(7)	18
Net loss	$ (3,102)	$ (31,422)
Net loss per share, basic (in dollars per share)	$ (1.15)	$ (35.75)
Net loss per share, diluted (in dollars per share)	$ (1.15)	$ (35.75)
Weighted-average common shares outstanding, basic (in shares)	2,694	879
Weighted-average common shares outstanding, diluted (in shares)	2,694	879
Product revenue
Revenue:
Total revenue	$ 6,004	$ 6,828
Cost of revenue:
Total cost of revenue	3,053	4,904
Service and other revenue
Revenue:
Total revenue	453	1,941
Cost of revenue:
Total cost of revenue	$ 466	$ 1,041

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482130/360-10-45-4

Bionano Genomics, Inc. 10-Q